Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
NBY's Cash-to-Debt is ranked higher than
88% of the 983 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NBY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NBY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.47  Med: N/A Max: No Debt
Current: No Debt
Equity-to-Asset 0.34
NBY's Equity-to-Asset is ranked lower than
83% of the 732 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NBY: 0.34 )
Ranked among companies with meaningful Equity-to-Asset only.
NBY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.48  Med: 0.53 Max: 0.83
Current: 0.34
-1.48
0.83
Interest Coverage No Debt
NBY's Interest Coverage is ranked higher than
84% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NBY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NBY' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 5
Altman Z-Score: -9.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -73.02
NBY's Operating Margin % is ranked higher than
53% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NBY: -73.02 )
Ranked among companies with meaningful Operating Margin % only.
NBY' s Operating Margin % Range Over the Past 10 Years
Min: -1603.8  Med: -109.49 Max: 17.47
Current: -73.02
-1603.8
17.47
Net Margin % -87.07
NBY's Net Margin % is ranked higher than
50% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. NBY: -87.07 )
Ranked among companies with meaningful Net Margin % only.
NBY' s Net Margin % Range Over the Past 10 Years
Min: -1441.56  Med: -105.85 Max: 17.2
Current: -87.07
-1441.56
17.2
ROE % -718.58
NBY's ROE % is ranked lower than
98% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NBY: -718.58 )
Ranked among companies with meaningful ROE % only.
NBY' s ROE % Range Over the Past 10 Years
Min: -1313.13  Med: -66.94 Max: 26.07
Current: -718.58
-1313.13
26.07
ROA % -109.58
NBY's ROA % is ranked lower than
88% of the 992 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NBY: -109.58 )
Ranked among companies with meaningful ROA % only.
NBY' s ROA % Range Over the Past 10 Years
Min: -300.82  Med: -41.38 Max: 17.13
Current: -109.58
-300.82
17.13
ROC (Joel Greenblatt) % -1366.64
NBY's ROC (Joel Greenblatt) % is ranked lower than
66% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: -369.38 vs. NBY: -1366.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NBY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5087.12  Med: -729.34 Max: 139.97
Current: -1366.64
-5087.12
139.97
3-Year Revenue Growth Rate -17.80
NBY's 3-Year Revenue Growth Rate is ranked lower than
72% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NBY: -17.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NBY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -32.65 Max: 36.3
Current: -17.8
0
36.3
3-Year EBITDA Growth Rate -51.20
NBY's 3-Year EBITDA Growth Rate is ranked lower than
94% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. NBY: -51.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NBY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -51.2  Med: -7.65 Max: 39.2
Current: -51.2
-51.2
39.2
3-Year EPS without NRI Growth Rate -48.90
NBY's 3-Year EPS without NRI Growth Rate is ranked lower than
91% of the 553 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NBY: -48.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NBY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: -7.2 Max: 35.7
Current: -48.9
-48.9
35.7
GuruFocus has detected 2 Warning Signs with NovaBay Pharmaceuticals Inc $NBY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NBY's 30-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:PLXP, NAS:ZSAN, OTCPK:IGXT, NAS:XOMA, NAS:EGLT, OTCPK:ANTB, OTCPK:AMEUF, NAS:BLPH, NAS:EIGR, NAS:PULM, NAS:CFRX, NAS:NTRP, NAS:KMPH, NAS:LPTX, NAS:RGLS, NAS:ITEK, NAS:APVO, NAS:AGLE, OTCPK:PMCB, NAS:AKTX » details
Headquarter Location:USA
NovaBay Pharmaceuticals Inc is a biopharmaceutical company engaged in commercializing & developing non-antibiotic anti-infective products to address the unmet therapeutic needs of the eye care market. Its product categories include NEUTROX & CELLERX.

NovaBay Pharmaceuticals Inc was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc., and subsequently changed its name to NovaBay Pharmaceuticals, Inc. In June 2010, the Company was reincorporated under the laws of the state of Delaware. The Company is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with two distinct product categories, Aganocides, for the eye care market, NeutroPhase, for wound care, and CelleRx for the dermatology market; and clinical stage Aganocide Compounds. The Company is focusing its Aganocide compounds into three large therapeutic markets: Urology - Statistically- significant and clinically-meaningful results from a Phase 2 clinical study of Auriclosene Irrigation Solution to reduce urinary catheter blockage and encrustation, Ophthalmology - NovaBay is developing an eye drop formulation of auriclosene (NVC-422) for treating adenoviral conjunctivitis, for which there is currently no FDA-approved treatment, Dermatology - Partnered with Galderma, a dermatology company, the Company is developing a gel formulation of auriclosene (NVC-422) for treating impetigo, a contagious skin infection. The Company has also developed NeutroPhase, a distinct class of molecule from the Aganocides. NeutroPhase is an FDA 510(k)-cleared Advanced Skin and Wound Cleanser. It has developed variations of the NeutroPhase product such as i-Lid Cleanser and CelleRx. The competitors for its Aganocides and for NeutroPhase include large and small pharmaceutical and medical device companies, such as Pfizer, Inc., Johnson & Johnson, Abbott Grp. Plc., GlaxoSmithKline Plc, Sanofi-Aventis SA, Novartis AG, Smith & Nephew Plc, C.R. Bard, Molnlycke, Lohman and Roucher, Johnson and Johnson, 3M, Puricore and Oculus Innovative Sciences. The Company's Aganocide product candidate, auriclosene (NVC-422), as well as many of the product candidates they expect to develop in the future. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of its product candidates are subject to extensive regulation by the FDA, state agencies and comparable regulatory authorities in other countries.

Ratios

vs
industry
vs
history
PB Ratio 12.46
NBY's PB Ratio is ranked lower than
81% of the 888 Companies
in the Global Biotechnology industry.

( Industry Median: 3.78 vs. NBY: 12.46 )
Ranked among companies with meaningful PB Ratio only.
NBY' s PB Ratio Range Over the Past 10 Years
Min: 1.77  Med: 5.23 Max: 148.03
Current: 12.46
1.77
148.03
PS Ratio 3.00
NBY's PS Ratio is ranked higher than
86% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.91 vs. NBY: 3.00 )
Ranked among companies with meaningful PS Ratio only.
NBY' s PS Ratio Range Over the Past 10 Years
Min: 1.15  Med: 4.76 Max: 1169.85
Current: 3
1.15
1169.85
Current Ratio 2.68
NBY's Current Ratio is ranked lower than
64% of the 977 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NBY: 2.68 )
Ranked among companies with meaningful Current Ratio only.
NBY' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.49 Max: 10.63
Current: 2.68
0.98
10.63
Quick Ratio 2.50
NBY's Quick Ratio is ranked lower than
63% of the 976 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NBY: 2.50 )
Ranked among companies with meaningful Quick Ratio only.
NBY' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 3.46 Max: 10.63
Current: 2.5
0.69
10.63
Days Inventory 150.67
NBY's Days Inventory is ranked lower than
56% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. NBY: 150.67 )
Ranked among companies with meaningful Days Inventory only.
NBY' s Days Inventory Range Over the Past 10 Years
Min: 104.77  Med: 221.93 Max: 524.69
Current: 150.67
104.77
524.69
Days Sales Outstanding 61.30
NBY's Days Sales Outstanding is ranked higher than
53% of the 627 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. NBY: 61.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
NBY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.1  Med: 57.3 Max: 94.54
Current: 61.3
0.1
94.54
Days Payable 119.32
NBY's Days Payable is ranked higher than
73% of the 433 Companies
in the Global Biotechnology industry.

( Industry Median: 55.32 vs. NBY: 119.32 )
Ranked among companies with meaningful Days Payable only.
NBY' s Days Payable Range Over the Past 10 Years
Min: 67.4  Med: 1400.67 Max: 20759.38
Current: 119.32
67.4
20759.38

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -104.70
NBY's 3-Year Average Share Buyback Ratio is ranked lower than
94% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: -11.90 vs. NBY: -104.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NBY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -104.7  Med: -28.4 Max: -3.4
Current: -104.7
-104.7
-3.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 16.90
NBY's Price-to-Net-Current-Asset-Value is ranked lower than
69% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. NBY: 16.90 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NBY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.16  Med: 5.9 Max: 118.99
Current: 16.9
2.16
118.99
Price-to-Tangible-Book 12.46
NBY's Price-to-Tangible-Book is ranked lower than
74% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. NBY: 12.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NBY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.91  Med: 5.39 Max: 95.39
Current: 12.46
1.91
95.39
Price-to-Median-PS-Value 0.63
NBY's Price-to-Median-PS-Value is ranked higher than
81% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. NBY: 0.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NBY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 1.03 Max: 226.23
Current: 0.63
0.26
226.23
Earnings Yield (Greenblatt) % -21.60
NBY's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.87 vs. NBY: -21.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NBY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -405  Med: -28.3 Max: 6.7
Current: -21.6
-405
6.7

More Statistics

Revenue (TTM) (Mil) $13.88
EPS (TTM) $ -0.82
Beta-1.29
Short Percentage of Float2.03%
52-Week Range $2.12 - 5.29
Shares Outstanding (Mil)15.31

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 19 27 35
EPS ($) -0.56 -0.16 -0.14
EPS without NRI ($) -0.56 -0.16 -0.14
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NBY

Headlines

Articles On GuruFocus.com
Novabay Pharmaceuticals' CEO Dr. Ramin Najafi Interviewed by The Life Sciences Report Jun 25 2015 
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 

More From Other Websites
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017 Jun 13 2017
NovaBay Pharmaceuticals to Present at the 7th Annual LD Micro Invitational May 30 2017
NovaBay Pharmaceuticals Receives Noncompliance Notice from NYSE MKT May 19 2017
NovaBay Pharmaceuticals Reports First Quarter 2017 Financial Results May 11 2017
NovaBay Pharmaceuticals to Hold 2017 First Quarter Conference Call on May 11, 2017 May 04 2017
Avenova from NovaBay Pharmaceuticals is Effective for Managing Dry Eye before Refractive and... May 02 2017
NovaBay's intelli-Case Can Safely and Effectively Disinfect Contact Lenses, CEOCFO Magazine Reports Apr 17 2017
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017 Mar 28 2017
Avenova from NovaBay Pharmaceuticals Effective for Painful Eye Condition Mar 28 2017
Edited Transcript of NBY earnings conference call or presentation 23-Mar-17 8:30pm GMT Mar 24 2017
NovaBay Pharmaceuticals Reports 2016 Full Year and Fourth Quarter Financial Results and Provides... Mar 23 2017
NovaBay Pharmaceuticals to Hold 2016 Fourth Quarter and Full Year Conference Call on March 23, 2017 Mar 16 2017
NovaBay Pharmaceuticals to Present Features and Benefits of the intelli-Case at FDA Public Advisory... Mar 09 2017
Explaining Innovative Drug Technologies Through Animation Mar 08 2017
NovaBay Pharmaceuticals to Present at 29th Annual ROTH Conference Mar 07 2017
Relief from Painful Dry Eye Can be a Real Valentine's Day Gift Feb 14 2017
NovaBay CEO Sees Continued Double-Digit Revenue Growth in 2017 Jan 30 2017
NovaBay Pharmaceuticals' "Avenova" Helping Patients with Contact Lens Intolerance Jan 27 2017
NovaBay Pharmaceuticals Announces Preliminary Sales for the Fourth Quarter of 2016 Jan 09 2017
NovaBay's Avenova Brings Quick Relief to Children Suffering from Eye Conditions, Writes Steven J.... Dec 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}